RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 Inhibitor of Interleukins 12 and 23 Slows Joint Destruction in Psoriatic Arthritis
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 18
SP 15
OP 16
DO 10.1177/155989771318005
UL http://mdc.sagepub.com/content/13/18/15.abstract
AB A prespecified integrated analysis of two Phase 3 clinical trials demonstrates that the monoclonal antibody ustekinumab reduces radiographic progression of joint disease in patients with active psoriatic arthritis. This article presents the integrated analysis of the two Phase 3 Multicenter, Randomised, Double-Blind, Placebo-Controlled Trials of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriasis Arthritis [PSUMMIT I and II; NCT01009086; NCT01077362].